The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 Jul 2011 13:01

For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Scancell Holdings plc attached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the Calculus Capital Limitednotification obligation:iii 4. Full name of shareholder(s) HSBC Global Custody (UK) Limited (if different from 3.):iv 5. Date of the transaction and date on which the threshold is crossed or 26 July 2011reached: v 6. Date on which issuer notified: 26 July 2011 7. Threshold(s) that is/are crossed or 10,11,12,13%reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering of to the triggering transaction shares transaction Number Number Number Number of voting % of voting rightsif possible of of of shares rights x using Shares Voting the ISIN Rights Direct Direct xi Indirect Direct Indirect CODE xii Ordinary Shares ISIN: 15,277,780 15,277,780 25,277,780 25,277,780 13.02 % GB00B39J5N63 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting % of voting financial date xvii Conversion rights instrument rights xix, xx instrument period refers to xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 25,277,780 13.02 %

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

N/A Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease N/Ato hold: 12. Date on which proxy holder will cease to hold N/Avoting rights: 13. Additional information: N/A 14. Contact name: Calculus Capital Limited 15. Contact telephone number: 0207 493 4940

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal entities) Contact address (registered office for legal entities) Phone number & email Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
8th May 20187:00 amRNSResult of the Open Offer and PDMR Shareholdings
23rd Apr 201812:43 pmRNSHolding(s) in Company
20th Apr 20184:32 pmRNSHolding(s) in Company
18th Apr 20182:29 pmRNSResult of Placing and Subscription and PDMR
18th Apr 201811:05 amRNSSecond Price Monitoring Extn
18th Apr 201811:00 amRNSPrice Monitoring Extension
18th Apr 20187:00 amRNSTechnology acquired from University of Nottingham
18th Apr 20187:00 amRNSProposed Placing, Subscription and Open Offer
3rd Apr 20187:00 amRNSManufacturing agreement with The PolyPeptide Group
16th Feb 201811:30 amRNSScancell to present at the Calculus Investor Forum
15th Feb 20187:15 amRNSHardman Res. - Validating multiple opportunities
15th Feb 20187:00 amRNSCollaboration agreement with ISA Pharmaceuticals
12th Feb 20187:00 amRNSPublication highlights potential of SCIB1 therapy
9th Feb 20187:00 amRNSEuropean patent application allowed for grant
8th Feb 20187:00 amRNSScancell member of team shortlisted for CRUK award
1st Feb 20187:00 amRNSDirector/PDMR Shareholding
30th Jan 20187:00 amRNSHalf-year Report
9th Jan 20187:00 amRNSScancell to collaborate with BioNTech
14th Dec 20177:00 amRNSScancell and CRUK to advance cancer immunotherapy
11th Oct 20179:44 amRNSResult of AGM
10th Oct 20177:00 amRNSDirectorate Change
14th Sep 20177:00 amRNSNotice of AGM
13th Sep 20177:00 amRNSFinal Results
11th Sep 20177:00 amRNSPresents Moditope Data at Immunotherapy Conference
29th Aug 20177:00 amRNSOncimmune and Scancell Present Autoantibodies Data
11th Jul 20177:00 amRNSContinued Progress on SCIB1
26th Jun 20177:00 amRNSDNA ImmunoBody Patent Granted in Europe
22nd May 201712:59 pmRNSHolding(s) in Company
19th May 20172:47 pmRNSHolding(s) in Company
19th May 20177:00 amRNSHolding(s) in Company
11th May 201712:09 pmRNSResults of Placing
11th May 20177:00 amRNSProposed Placing to Raise up to £5.0 million
13th Apr 201712:39 pmRNSChange of Registered Office
20th Mar 20177:00 amRNSImmuno-Oncology Summit Europe 2017
13th Mar 20177:15 amRNSHardman Research: SCIB development update
1st Mar 20177:00 amRNSHolding(s) in Company
31st Jan 20177:00 amRNSInterim Results
30th Jan 20177:00 amRNSPartnership to Advance Lung Cancer Clinical Trials
3rd Jan 201711:33 amRNSResearch Update - Amendment
3rd Jan 20177:00 amRNSResearch Update
14th Nov 20167:00 amRNSWorld Immunotherapy Congress and Biotech and Money
18th Oct 20165:42 pmRNSResults of AGM
10th Oct 20167:00 amRNSPreparing SCIB2 for clinical study in lung cancer
26th Sep 20167:15 amRNSHardman Report: New frontiers in T-cell activation
23rd Sep 20165:24 pmRNSNotice of AGM - Amendment
23rd Sep 20163:28 pmRNSNotice of AGM
16th Sep 20167:00 amRNSFinal Results
7th Sep 20167:00 amRNSNewsMakers in the Biotech Industry Conference
22nd Aug 20167:00 amRNSAppointment of Non-Executive Director
21st Jul 20167:00 amRNSEurogentec manufacturing agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.